CL2020002546A1 - Compuestos dirigidos a brm y métodos de uso asociados - Google Patents
Compuestos dirigidos a brm y métodos de uso asociadosInfo
- Publication number
- CL2020002546A1 CL2020002546A1 CL2020002546A CL2020002546A CL2020002546A1 CL 2020002546 A1 CL2020002546 A1 CL 2020002546A1 CL 2020002546 A CL2020002546 A CL 2020002546A CL 2020002546 A CL2020002546 A CL 2020002546A CL 2020002546 A1 CL2020002546 A1 CL 2020002546A1
- Authority
- CL
- Chile
- Prior art keywords
- target protein
- present disclosure
- brm
- compounds
- associated methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación se refiere a compuestos bifuncionales, que encuentran utilidad como moduladores de SMARCA2 o BRM (proteína diana). En particular, la presente divulgación está dirigida a compuestos bifuncionales, que contienen en un extremo un ligando que se une a la ubiquitina ligasa de Von Hippel-Lindau E3, y en el otro extremo un resto que se une a la proteína diana, de modo que la proteína diana es colocada cerca de la ubiquitina ligasa para efectuar la degradación (e inhibición) de la proteína diana. La presente divulgación exhibe una amplia gama de actividades farmacológicas asociadas con la degradación / inhibición de la proteína diana. Las enfermedades o trastornos que resultan de la agregación o acumulación de la proteína diana se tratan o se previenen con compuestos y composiciones de la presente divulgación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862651186P | 2018-04-01 | 2018-04-01 | |
US201962797754P | 2019-01-28 | 2019-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020002546A1 true CL2020002546A1 (es) | 2021-01-29 |
Family
ID=66175525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002546A CL2020002546A1 (es) | 2018-04-01 | 2020-10-01 | Compuestos dirigidos a brm y métodos de uso asociados |
Country Status (17)
Country | Link |
---|---|
US (2) | US20190300521A1 (es) |
EP (1) | EP3774789A1 (es) |
JP (2) | JP2021520350A (es) |
KR (1) | KR20210005037A (es) |
CN (1) | CN112166114A (es) |
AU (3) | AU2019249849C1 (es) |
BR (1) | BR112020020196A2 (es) |
CA (1) | CA3094305A1 (es) |
CL (1) | CL2020002546A1 (es) |
CO (1) | CO2020013762A2 (es) |
CR (1) | CR20200527A (es) |
IL (1) | IL277677A (es) |
MX (1) | MX2020010368A (es) |
PE (1) | PE20212108A1 (es) |
PH (1) | PH12020500663A1 (es) |
SG (1) | SG11202008898UA (es) |
WO (1) | WO2019195201A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020010420A (es) | 2018-04-04 | 2020-12-11 | Arvinas Operations Inc | Moduladores de la proteólisis y métodos asociados de uso. |
JP7387630B2 (ja) * | 2018-04-26 | 2023-11-28 | オーリジーン オンコロジー リミテッド | Smarca2/4分解剤としてのピリダジン誘導体 |
US11771697B2 (en) | 2018-04-30 | 2023-10-03 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (PBRM1) |
CN112912376A (zh) | 2018-08-20 | 2021-06-04 | 阿尔维纳斯运营股份有限公司 | 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物 |
EP3870235A1 (en) | 2018-10-24 | 2021-09-01 | F. Hoffmann-La Roche AG | Conjugated chemical inducers of degradation and methods of use |
EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
JP2022540935A (ja) | 2019-07-17 | 2022-09-20 | アルビナス・オペレーションズ・インコーポレイテッド | タウタンパク質標的化化合物および関連する使用方法 |
JP2022550437A (ja) * | 2019-10-01 | 2022-12-01 | アルヴィナス・オペレーションズ・インコーポレイテッド | Brm標的化化合物および関連使用方法 |
US20230124700A1 (en) * | 2019-10-16 | 2023-04-20 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof |
CN114599428A (zh) * | 2019-10-28 | 2022-06-07 | 豪夫迈·罗氏有限公司 | 双功能化合物 |
JP2023511472A (ja) * | 2019-10-29 | 2023-03-20 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のための二官能性化合物 |
TW202136242A (zh) | 2019-12-23 | 2021-10-01 | 美商凱麥拉醫療公司 | Smarca降解劑及其用途 |
AU2021213258B2 (en) * | 2020-01-29 | 2024-05-02 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
AU2021214767A1 (en) | 2020-01-29 | 2022-07-28 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
JP2023529908A (ja) | 2020-06-09 | 2023-07-12 | プレリュード・セラピューティクス・インコーポレイテッド | Brm標的化化合物及び関連する使用方法 |
IL299860A (en) | 2020-07-21 | 2023-03-01 | Genentech Inc | Antibody-conjugated chemical factors for the discharge of BRM and their methods |
US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
EP4240743A1 (en) * | 2020-11-06 | 2023-09-13 | Prelude Therapeutics, Incorporated | Brm targeting compounds and associated methods of use |
EP4259144A1 (en) * | 2020-12-09 | 2023-10-18 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
TW202241855A (zh) * | 2021-01-27 | 2022-11-01 | 美商富曼西公司 | 用於防治無脊椎有害生物之唑類化合物 |
JP2024515619A (ja) | 2021-04-16 | 2024-04-10 | アルビナス・オペレーションズ・インコーポレイテッド | Bcl6タンパク質分解の調節因子および関連する使用方法 |
EP4333899A1 (en) | 2021-05-05 | 2024-03-13 | Biogen MA Inc. | Compounds for targeting degradation of bruton's tyrosine kinase |
AU2022272181A1 (en) * | 2021-05-10 | 2023-11-02 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
US11767330B2 (en) | 2021-07-06 | 2023-09-26 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
UY39844A (es) | 2021-07-07 | 2023-01-31 | Biogen Ma Inc | Compuestos para la degradación selectiva de las proteínas irak4 |
EP4366834A1 (en) | 2021-07-07 | 2024-05-15 | Biogen MA Inc. | Compounds for targeting degradation of irak4 proteins |
WO2023287787A1 (en) * | 2021-07-13 | 2023-01-19 | Prelude Therapeutics, Incorporated | Brm targeting compounds and associated methods of use |
WO2023093728A1 (zh) * | 2021-11-23 | 2023-06-01 | 江苏先声药业有限公司 | Brm选择性降解剂化合物及其应用 |
WO2023097031A1 (en) * | 2021-11-24 | 2023-06-01 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
WO2023096987A1 (en) * | 2021-11-24 | 2023-06-01 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
WO2023129506A1 (en) * | 2021-12-28 | 2023-07-06 | Board Of Regents, The University Of Texas System | Potent and selective smarca2 degrading chimeric molecules as cancer therapeutics |
AR128330A1 (es) | 2022-01-26 | 2024-04-17 | Genentech Inc | Inductores químicos de degradación conjugados con anticuerpo y métodos de estos |
AR128331A1 (es) | 2022-01-26 | 2024-04-17 | Genentech Inc | Inductores químicos de degradación conjugados con anticuerpos y métodos de estos |
US20230416240A1 (en) | 2022-06-16 | 2023-12-28 | Prelude Therapeutics Incorporated | Kat6 targeting compounds |
WO2024002375A1 (zh) * | 2022-06-30 | 2024-01-04 | 甘李药业股份有限公司 | 一种用作smarca2/4抑制剂的化合物及其应用 |
CN115353468B (zh) * | 2022-08-19 | 2023-06-30 | 安阳工学院 | 一种对甲苯磺酰氧基取代低聚乙二醇丙酸叔丁酯的制备方法 |
WO2024107711A1 (en) | 2022-11-15 | 2024-05-23 | Prelude Therapeutics Incorporated | Brm targeting compounds and associated methods of use |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
MX358660B (es) * | 2012-01-12 | 2018-08-30 | Univ Yale | Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3. |
RU2738833C9 (ru) * | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
KR20230119040A (ko) * | 2015-01-20 | 2023-08-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 안드로겐 수용체의 표적화된 분해를 위한 화합물 및방법 |
MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
US10730870B2 (en) | 2015-03-18 | 2020-08-04 | Arvinas Operations, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
US20170008904A1 (en) * | 2015-07-10 | 2017-01-12 | Arvinas, Inc. | Mdm2-based modulators of proteolysis and associated methods of use |
WO2017011590A1 (en) * | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS CONTAINING BROMODOMAIN |
KR20180097530A (ko) * | 2015-11-02 | 2018-08-31 | 예일 유니버시티 | 단백질분해 표적화 키메라 화합물(Proteolysis Targeting Chimera compound) 및 그의 제조 및 사용 방법 |
JP2020506922A (ja) | 2017-01-31 | 2020-03-05 | アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. | セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物 |
CN107698657A (zh) * | 2017-09-26 | 2018-02-16 | 中国药科大学 | 基于vhl配体和bet抑制剂诱导bet降解的双功能分子及其制备和应用 |
-
2019
- 2019-04-01 BR BR112020020196-0A patent/BR112020020196A2/pt unknown
- 2019-04-01 EP EP19717685.2A patent/EP3774789A1/en active Pending
- 2019-04-01 KR KR1020207031366A patent/KR20210005037A/ko active IP Right Grant
- 2019-04-01 AU AU2019249849A patent/AU2019249849C1/en active Active
- 2019-04-01 WO PCT/US2019/025254 patent/WO2019195201A1/en unknown
- 2019-04-01 US US16/372,345 patent/US20190300521A1/en not_active Abandoned
- 2019-04-01 PE PE2020001522A patent/PE20212108A1/es unknown
- 2019-04-01 JP JP2020553643A patent/JP2021520350A/ja active Pending
- 2019-04-01 SG SG11202008898UA patent/SG11202008898UA/en unknown
- 2019-04-01 CR CR20200527A patent/CR20200527A/es unknown
- 2019-04-01 MX MX2020010368A patent/MX2020010368A/es unknown
- 2019-04-01 CA CA3094305A patent/CA3094305A1/en active Pending
- 2019-04-01 CN CN201980036295.9A patent/CN112166114A/zh active Pending
-
2020
- 2020-09-15 PH PH12020500663A patent/PH12020500663A1/en unknown
- 2020-09-30 IL IL277677A patent/IL277677A/en unknown
- 2020-10-01 CL CL2020002546A patent/CL2020002546A1/es unknown
- 2020-10-30 CO CONC2020/0013762A patent/CO2020013762A2/es unknown
-
2022
- 2022-06-10 AU AU2022204042A patent/AU2022204042A1/en not_active Abandoned
-
2023
- 2023-02-10 US US18/108,045 patent/US20240076295A1/en active Pending
- 2023-02-17 JP JP2023023039A patent/JP2023071767A/ja active Pending
-
2024
- 2024-05-08 AU AU2024203058A patent/AU2024203058A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202008898UA (en) | 2020-10-29 |
CR20200527A (es) | 2021-04-09 |
AU2024203058A1 (en) | 2024-05-30 |
US20190300521A1 (en) | 2019-10-03 |
PH12020500663A1 (en) | 2021-06-07 |
AU2022204042A1 (en) | 2022-06-30 |
JP2023071767A (ja) | 2023-05-23 |
CN112166114A (zh) | 2021-01-01 |
MX2020010368A (es) | 2021-01-08 |
JP2021520350A (ja) | 2021-08-19 |
RU2020135754A (ru) | 2022-05-04 |
PE20212108A1 (es) | 2021-11-04 |
RU2020135754A3 (es) | 2022-05-04 |
EP3774789A1 (en) | 2021-02-17 |
US20240076295A1 (en) | 2024-03-07 |
CA3094305A1 (en) | 2019-10-10 |
BR112020020196A2 (pt) | 2021-01-26 |
KR20210005037A (ko) | 2021-01-13 |
IL277677A (en) | 2020-11-30 |
CO2020013762A2 (es) | 2021-01-18 |
WO2019195201A1 (en) | 2019-10-10 |
AU2019249849B2 (en) | 2022-03-17 |
AU2019249849C1 (en) | 2022-09-29 |
AU2019249849A1 (en) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002546A1 (es) | Compuestos dirigidos a brm y métodos de uso asociados | |
CO2019009145A2 (es) | Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso | |
CO2019005712A2 (es) | Protac dirigidos a la proteína tau y métodos asociados de uso | |
CO2019007091A2 (es) | Derivados de tetrahidronaftaleno y tetrahidroisoquinolina como degradadores del receptor de estrogeno | |
CO2019007892A2 (es) | Moléculas quiméricas dirigidas a la proteólisis del egfr y métodos asociados de uso | |
CO2019007894A2 (es) | Compuestos y métodos para la degradación dirigida de polipéptidos de fibrosarcoma acelerado rápidamente | |
CO2020013864A2 (es) | Moduladores de la proteólisis y métodos asociados de uso | |
CO2022006490A2 (es) | Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6 | |
CO2021000151A2 (es) | Inhibidores de pd-1/pd-l1 | |
CL2020002082A1 (es) | Inhibidores pd-1/pd-l1. | |
CO2019011543A2 (es) | Inhibidores de pd-1/pd-l1 | |
BR112018067408A2 (pt) | formas sólidas de um inibidor de acc de tienopirimidinadiona e métodos para a produção das mesmas | |
BR112017019751A2 (pt) | composto bifuncional, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou um distúrbio, e para degradar uma proteína alvo em uma célula | |
CL2021003196A1 (es) | Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 (divisional de solicitud n° 201902850) | |
CL2023003021A1 (es) | Moduladores de la proteólisis bcl6 y métodos de uso asociados, | |
CL2019000304A1 (es) | Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento. | |
BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
BR112018016968A2 (pt) | derivados de carboxamida úteis como inibidores de rsk | |
EA202091731A1 (ru) | Ингибиторы аутотаксина и их применения | |
CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
CO2020015377A2 (es) | Moduladores de la expresión de apol1 | |
CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
UY38472A (es) | Moduladores de la expresión de foxp3 | |
MX2020003554A (es) | Moduladores de la expresion de enac. |